Relationship between myocardial damage and C-reactive protein levels immediately after onset of acute myocardial infarction.
暂无分享,去创建一个
O. Tochikubo | M. Kosuge | T. Ishikawa | K. Kimura | T. Endo | S. Umemura | Y. Hongo | M. Shimizu
[1] H. Tomoda,et al. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. , 2000, American heart journal.
[2] O. Tochikubo,et al. Relation between C-reactive protein levels on admission and pattern of acute myocardial infarction onset. , 2000, The American journal of cardiology.
[3] M. Hori,et al. Evidence for the delayed effect in human ischemic preconditioning: prospective multicenter study for preconditioning in acute myocardial infarction. , 1999, Journal of the American College of Cardiology.
[4] A. Rebuzzi,et al. Enhanced inflammatory response in patients with preinfarction unstable angina. , 1999, Journal of the American College of Cardiology.
[5] E. Masini,et al. Cardioprotective activity of endogenous and exogenous nitric oxide on ischaemia reperfusion injury in isolated guinea pig hearts , 1999, Inflammation Research.
[6] F. Neumann,et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. , 1999, Journal of the American College of Cardiology.
[7] C. Visser,et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? , 1999, Circulation.
[8] A. Harken,et al. Reduction of infarct size in the rat heart by LPS preconditioning is associated with expression of angiogenic growth factors and increased capillary density. , 1999, Shock.
[9] A. Rebuzzi,et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. , 1999, Circulation.
[10] A. Kastrati,et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. , 1998, Circulation.
[11] H. Crijns,et al. Flecainide reduces tachycardia-induced electrical remodeling of the atria , 1998 .
[12] S. Ogawa,et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. , 1997, Circulation.
[13] S. Thompson,et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.
[14] Eric Boersma,et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour , 1996, The Lancet.
[15] L. Kuller,et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.
[16] A. Pasternack,et al. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. , 1996, European heart journal.
[17] A. Rebuzzi,et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.
[18] D. Yellon,et al. Preconditioning the human myocardium , 1993, The Lancet.
[19] O Pahlm,et al. Performance of the automated complete Selvester QRS scoring system in normal subjects and patients with single and multiple myocardial infarctions. , 1992, Journal of the American College of Cardiology.
[20] E. Braunwald,et al. Unstable angina. A classification. , 1989, Circulation.
[21] K. Nademanee,et al. Characteristics and clinical significance of silent myocardial ischemia in unstable angina. , 1986, The American journal of cardiology.
[22] H W Woo,et al. Advantages and applications of the centerline method for characterizing regional ventricular function. , 1986, Circulation.
[23] M. Cohen,et al. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. , 1985, Journal of the American College of Cardiology.
[24] K. Pietilä,et al. Acute phase reaction, infarct size and in-hospital morbidity in myocardial infarction patients treated with streptokinase or recombinant tissue type plasminogen activator. , 1991, Annals of medicine.
[25] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.